Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy

Status unconfirmed · Phase 2

Conditions studied: Diabetic Polyneuropathy

In brief

This clinical trial is to determine an effective dosage and to study the safety of an investigational drug -lidorestat (IDD-676)- which is intended to stop or slow the progression of diabetic peripheral neuropathy.

Key facts

Study ID

NCT00043797

Run by

The Institute for Diabetes Discovery, LLC

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Scottsdale Medical Specialists — Scottsdale, Arizona, United States
• Glendale Adventist Medical Center — Glendale, California, United States
• Marin Endocrinology Associates — Greenbrae, California, United States
• Diabetes & Endocrine Associates — La Jolla, California, United States
• Radiant Research — Gainesville, Florida, United States
• University of Miami, Dept. of Diabetes, Endocrinology & Metabolism — Miami, Florida, United States
• Johns Hopkins University - School of Medicine — Baltimore, Maryland, United States
• Brody School of Medicine, East Carolina University — Greenville, North Carolina, United States
• University of Oklahoma — Oklahoma City, Oklahoma, United States
• University of Texas, Southwest Medical Center — Dallas, Texas, United States
• Diabetes & Glandular Disease Clinic — San Antonio, Texas, United States
• Toronto General Hospital, University Health Network — Toronto, Ontario, Canada
• Centre de Recherche — Laval, Quebec, Canada
• Hospital de L'Enfant-Jesus — Québec, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.